Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Issue title: Translational Pathology of Early Cancer
Guest editors: Sudhir Srivastavax and William E. Grizzley
Article type: Research Article
Authors: Cole, Kimberlya | Tabernero, Mariab | Anderson, Karen S.c; *
Affiliations: [a] Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston MA, USA | [b] Hospital Universitario de Salamanca, Laboratorio Unidad de Investigacion, Salamanca, Spain | [c] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, USA | [x] Cancer Biomarkers Research Group, Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA | [y] Department of Pathology, Division of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
Correspondence: [*] Corresponding author: Karen S, Anderson, M.D., Ph.D., HIM 416, 77 Ave Louis Pasteur, Dana-Farber Cancer Institute, Harvard Medical School, Boston MA, 02115, USA. Tel.: +1 617 632 5931; Fax: +1 617 632 3966; E-mail: [email protected].
Abstract: Breast cancer is the second leading cause of cancer death in women in the United States. While mammography and breast magnetic resonance imaging (MRI) improve detection of early disease, there remains an unmet need for biomarkers for risk stratification, early detection, prediction, and disease prognosis. A number of early breast lesions, from atypical hyperplasias to carcinomas in situ, are associated with an increased risk of developing subsequent invasive breast carcinoma. The recent development of genomic, epigenomic, and proteomic tools for tissue biomarker detection, including array CGH, RNA expression microarrays, and proteomic arrays have identified a number of potential biomarkers that both identify patients at increased risk, as well as provided insights into the pathology of early breast cancer development. This chapter focuses on the detection and application of tissue and serum biomarkers for the identification and risk stratification of early breast cancer lesions.
Keywords: Breast cancer, benign breast disease, biomarkers
DOI: 10.3233/CBM-2011-0187
Journal: Cancer Biomarkers, vol. 9, no. 1-6, pp. 177-192, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]